Bringing the fundamentals into focus…
Back to Neogen Corporation
How Neogen Corporation stacks up
NEOG · against 355 other Healthcare companies of similar size
Valuation
39/ 100
Below the middle of the pack.
Ranked #233 of 356 · scores higher than 34% of peers
Bars: peers in each 10-point band of the valuation score31 peers with a valuation score of 30–39, including NEOG · Click a bar to see the companies
Why valuation scores 39?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield, which is weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -2.1% vs peer median 1.5%
- EBITDA yield is close to the peer norm. EBITDA yield: 2.7% vs peer median 4.0%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.9% vs peer median 0.0%
Metric by metric
Position: dot = NEOG, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | NEOG | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 347 reported | -2.1% | 2.3% | 28% | 30% | |
| EBITDA yieldHigher is better · 353 reported | 3.4% | 4.6% | 43% | 50% | |
| Free cash flow yieldHigher is better · 179 reported | 1.2% | -0.0% | 58% | 20% | |
| Book yieldHigher is better · 347 reported | 79.1% | 32.1% | 90% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around NEOGScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score